William J. Gradishar, MD, on Triple-Negative Breast Cancer: Expert Perspective on the KEYNOTE-086 Trial Results

Posted: Wednesday, July 5, 2017

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses a phase II study of pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.